Clinical trials: IrAE
IrAE, Immune-related Adverse Event
Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICI) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard…
- Conditions
- IrAE, Immune-related Adverse Event, Diarrhea, Colitis
- Trial name
- NCT06337695
- Testing
- Vedolizumab
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- AHS Cancer Control Alberta
Hepatocellular Carcinoma (HCC), IrAE
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
This study is a prospective, randomized, single-center randomized controlled clinical trial to investigate the safety and efficacy of ondansetron in reducing the toxicity associated with immune checkpoint inhibitor treatment.
- Trial name
- NCT07381634
- Testing
- ondansetron
- Where
- China
- Volunteers
- 134 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Cancer, Immunotherapy
Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy
During the immune checkpoint inhibitor therapy (ICIT), most of the patients stay at home, but there is lacking of the studies to explore their physical and psychological distress, financial toxicity, care needs, and quality of…
- Conditions
- Cancer, Immunotherapy, IrAE, Distress, Emotional
- Trial name
- NCT06461780
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE
Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance
This study is a Phase II, two-cohort, multicenter, two-stage clinical trial. It plans to enroll 72 subjects with solid tumors who discontinued prior ICI therapy due to irAE.
- Trial name
- NCT07313202
- Testing
- Ivarmacitinib
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
IrAE, Hematologic Disorder
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
This study is a single-arm clinical trial designed to evaluate the safety and efficacy of golidocitinib in patients with refractory, immune-related hematologic toxicity in advanced lung cancer.
- Conditions
- IrAE, Hematologic Disorder, Lung Cancer (Locally Advanced or Metastatic)
- Trial name
- JACKPOT22 (NCT07303881)
- Testing
- golidocitinib
- Where
- China
- Volunteers
- 16 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
IrAE
Thymosin Alpha-1 for irAE Secondary to ICIs
Thymosin alpha-1 (Tα-1) has shown clinical benefits in patients whose immune functions are severely compromised or ineffective. Therefore, this study is attempted to explore whether Tα-1 could be used as a therapeutic option for…
- Trial name
- NCT06178146
- Testing
- Thymosin Alpha1, Immunosuppressant
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jun Wang